Comparison of Transcriptomic Analysis between IDH1 Mutant and Wild‐type of Lower Grade Glioma

Among glioma patients, the existence of isocitrate dehydrogenase (IDH) 1 mutation is critical in their treatment and prognosis. However, effector genes specifically affected by IDH1 mutation are not identified yet, nor their biological mechanisms. Here, we show a few candidate genes selected by informatics methods, and suggest that inflammasome related CASP‐1 , and ‐4 as the effector genes of glioma and future possibility of drug relocations. According to Cox regression analysis, 23, 78 genes were confirmed in the groups of protective genes in IDH1 mutant type and wild type, and 68, 170 genes in risk groups in mutant and wild type each. Interestingly, there were only two overlaps between the mutation group and wild type group within the risk factors, and none within the protective factors. These indicate that the pathophysiological mechanisms directed by the IDH1 mutant type and wild type in glioma are different. The results of Cox regression and GO term enrichment showed that many of the pathways in IDH1 wild type risk group are related to inflammation response, which are known to be pathologic in many different types of cancers. Among the genes related to the pathways, we chose CASP‐1 and ‐4 , which are involved in inflammasome functions, and were able to find that high expression of the genes are related with the low survival of the patients, according to the Kaplan‐Meier curves. In conclusion, this research suggests new possibilities of treatment targeted to the genes mentioned above, such as drug relocations. Support or Funding Information This study was supported by grants of Basic Research Project in Science and Engineering, funded by the Ministry of Science, Technology and Information, Republic of Korea (Grant no. 2019R1F1A1054920) and of the University Innovation Support Project (UISP) through the National Research Foundation (NRF) funded by MOE.